Symbols

LPCN

Lipocine·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LPCN

Lipocine Inc.

A biopharmaceutical company focused on developing therapeutics for central nervous system ("CNS") and metabolic disorders

Industry

Pharmaceutical

Established Date

06/19/1997

Listing Date

03/21/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.lipocine.com

Security Type

Common stock

Office address

675 Arapeen Drive , Suite 202 , Salt Lake City , Utah 84108

Business

Introduction

Lipocine Inc., incorporated in Delaware on June 19, 1997, is a specialized biopharmaceutical company dedicated to the application and development of its oral drug delivery technology in the biopharmaceutical field. Lipocine's proprietary drug delivery technology improves patient compliance and safety through oral regimens. The company's main development projects are for oral drug solutions with poor absorption effect. This type of drug has poor absorption effect and the dose is not enough to make the effect of the drug reach the circulatory system. The company has a series of patented product candidates with the following characteristics: good pharmacokinetic properties, conducive to meeting low dose requirements, bypassing initial metabolic processes, reducing side effects, and eliminating gastrointestinal interactions that limit drug activity. The company's product candidate, LPCN 1021, is a third-stage oral testosterone replacement therapy (TRT) with a dosage of twice a day, which is very convenient.

Company Financials

EPS

LPCN has released its 2025 Q3 earnings. EPS was reported at -0.59, versus the expected -0.54, missing expectations. The chart below visualizes how LPCN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LPCN has released its 2025 Q3 earnings report, with revenue of 114.57K, reflecting a YoY change of NaN%, and net profit of -3.19M, showing a YoY change of -43.63%. The Sankey diagram below clearly presents LPCN's revenue sources and cost distribution.